Effect of Therapeutic Inhibition of TNF on Circulating Endothelial Progenitor Cells in Patients with Rheumatoid Arthritis

Table 1

F/M	14/3
Age—yrs
Mean ± SD (range)	50.4±14.4 (26–68)
Disease duration—months
Mean ± SD (range)	103.0±104.4 (24–360)
DAS28 baseline
Mean ± SD (range)	5.2±1.1 (4.27–7.78)
DAS28 followup
Mean ± SD (range)	3.3±1.3 (0.56–4.03)*
Glucocorticoid dose (mg) baseline
Mean ± SD (range)	7.5±5 (5–20)**
Glucocorticoid dose (mg) followup
Mean ± SD (range)	5.2±0.6 (5–7.5)**
Methotrexate	10/17
Leflunomide	3/17
Sulfasalazine	3/17
Adalimumab	3/17
Etanercept	14/17

DAS28: disease activity score 28.
^∗𝑃=0.001 versus baseline value, **prednisone-equivalent.